Somatix Therapy
Executive Summary
Company's Phase I GVAX gene therapy protocol for prostate cancer is the first approved by NIH's Recombinant DNA Advisory Committee under the new accelerated review procedures. GVAX is designed to produce an immune response that "seeks out and destroys remaining or metastatic tumors" by genetically modifying the patient's own cells to produced the immunostimulant GM-CSF, Somatix says. Trials of GVAX for renal cell carcinoma and advanced melanoma are already under way
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth